Biotest AG's CFO Martin Möller to Depart

Biotest AG, based in Dreieich, Germany, has announced that Martin Möller, its Chief Financial Officer (CFO), will leave the company as planned when his contract ends on March 15, 2025. The supervisory board has initiated the search for a successor and aims to fill the CFO position soon.

Despite his departure, Möller will continue to support Biotest AG in an advisory capacity. The company emphasizes this transition period to ensure stability and continuity in its financial operations. Biotest AG specializes in biological therapeutics derived from human plasma, focusing on clinical immunology, hematology, and intensive care medicine.

Biotest is part of the Grifols Group and its shares are listed in the Prime Standard on the German Stock Exchange. The announcement underscores both continuity and the preparatory steps for a seamless transition.